Adverse events following HPV vaccination: 11 years of surveillance in Australia A Phillips, M Hickie, J Totterdell, J Brotherton, A Dey, R Hill, T Snelling, ... Vaccine 38 (38), 6038-6046, 2020 | 29 | 2020 |
Can a continuous quality improvement program create culturally safe emergency departments for Aboriginal people in Australia? A multiple baseline study T Gadsden, G Wilson, J Totterdell, J Willis, A Gupta, A Chong, A Clarke, ... BMC health services research 19, 1-15, 2019 | 27 | 2019 |
Recognition and management of protracted bacterial bronchitis in Australian aboriginal children: a knowledge translation approach P Laird, R Walker, M Lane, J Totterdell, AB Chang, A Schultz Chest 159 (1), 249-258, 2021 | 23 | 2021 |
Contribution of maternal age, medical and obstetric history to maternal and perinatal morbidity/mortality for women aged 35 or older JM Morris, J Totterdell, YS Bin, JB Ford, CL Roberts Australian and New Zealand Journal of Obstetrics and Gynaecology 58 (1), 91-97, 2018 | 20 | 2018 |
Prevalence of chronic wet cough and protracted bacterial bronchitis in Aboriginal children P Laird, J Totterdell, R Walker, AB Chang, A Schultz ERJ Open Research 5 (4), 2019 | 17 | 2019 |
Safety of live attenuated herpes zoster vaccine in adults 70–79 years: a self-controlled case series analysis using primary care data from Australia’s MedicineInsight program J Totterdell, A Phillips, C Glover, K Chidwick, J Marsh, T Snelling, ... Vaccine 38 (23), 3968-3979, 2020 | 14 | 2020 |
Anticoagulation strategies in non–critically ill patients with Covid-19 ZK McQuilten, B Venkatesh, V Jha, J Roberts, SC Morpeth, JA Totterdell, ... NEJM evidence 2 (2), EVIDoa2200293, 2023 | 11 | 2023 |
ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial JT Denholm, B Venkatesh, J Davis, AC Bowen, NE Hammond, V Jha, ... Trials 23 (1), 1014, 2022 | 10 | 2022 |
OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule GP Chacon, MJ Estcourt, J Totterdell, DE Campbell, KP Perrett, JA Marsh, ... BMJ open 10 (12), e042838, 2020 | 6 | 2020 |
A randomized trial of nafamostat for Covid-19 SC Morpeth, B Venkatesh, JA Totterdell, GM McPhee, RK Mahar, M Jones, ... NEJM evidence 2 (11), EVIDoa2300132, 2023 | 5 | 2023 |
The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants … MA Jones, T Graves, B Middleton, J Totterdell, TL Snelling, JA Marsh Trials 21, 1-19, 2020 | 4 | 2020 |
FeBRILe3 Project: protocol for a prospective pragmatic, multisite observational study and safety evaluation assessing Fever, Blood cultures and Readiness for discharge in … AO Mace, AC Martin, J Ramsay, J Totterdell, JA Marsh, T Snelling BMJ open 10 (5), e035992, 2020 | 3 | 2020 |
Bayesian hidden Markov models in DNA sequence segmentation using R: the case of Simian Vacuolating virus (SV40) JA Totterdell, D Nur, KL Mengersen Journal of Statistical Computation and Simulation 87 (14), 2799-2827, 2017 | 3 | 2017 |
Transparent reporting of adaptive clinical trials using concurrently randomised cohorts IC Marschner, M Jones, JA Totterdell, RK Mahar, TL Snelling, SYC Tong BMJ medicine 2 (1), 2023 | 2 | 2023 |
Anticoagulation and antiplatelet strategies in non-critically ill patients with COVID-19 Z McQuilten, B Venkatesh, V Jha, J Roberts, S Morpeth, J Totterdell, ... Blood 140 (Supplement 1), 326-328, 2022 | 2 | 2022 |
Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular … JA Totterdell, GP Chacon, MJ Estcourt, M Jones, P Richmond, TL Snelling, ... Trials 23 (1), 121, 2022 | 2 | 2022 |
Aboriginal identification in hospitals quality improvement program: Evaluation findings G Wilson, J Willis, J Totterdell, A Gupta, A Chong, A Clarke, M Winters, ... North Sydney: Centre for Aboriginal Health and Centre for Epidemiology and …, 2017 | 2 | 2017 |
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate MP Hernández-Mitre, SC Morpeth, B Venkatesh, TE Hills, J Davis, ... Clinical Microbiology and Infection 30 (6), 743-754, 2024 | 1 | 2024 |
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of nafamostat and camostat mesylate randomised clinical trials HMM Patricia, M Susan, V Balasubramanian, H Thomas, D Joshua, ... Clinical Microbiology and Infection, 2024 | 1 | 2024 |
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted … P Fathima, M Jones, R D’Souza, J Totterdell, N Andric, P Abbott, ... Trials 25 (1), 387, 2024 | | 2024 |